Syngene International Limited has announced major leadership changes effective 2026, with Kiran Mazumdar Shaw transitioning to Executive Chairperson from April 01, 2026, and Siddharth Mittal being appointed as Managing Director & CEO from July 01, 2026. Peter Bains will resign as MD & CEO on June 30, 2026. Both new appointments are for five-year terms and require shareholder approval.
Syngene International Limited has announced a comprehensive leadership restructuring that will see significant changes in its top management positions starting in 2026. The Board of Directors, following recommendations from the Nomination and Remuneration Committee, has approved multiple key appointments and role transitions that will shape the company's future direction.
Leadership Transition Details
The most notable change involves Ms. Kiran Mazumdar Shaw's elevation from Non-Executive Chairperson to Executive Chairperson, marking her transition to a Key Managerial Personnel role. This appointment will be effective from April 01, 2026, for a period of five years, subject to shareholder approval.
Executive Appointments and Departures
Mr. Peter Bains will step down from his position as Managing Director & Chief Executive Officer, with his resignation taking effect from the close of business hours on June 30, 2026. His departure will be followed by the appointment of Mr. Siddharth Mittal as Additional Director, designated as Managing Director & Chief Executive Officer.
Mr. Mittal's appointment includes designation as a Key Managerial Personnel and membership in the Executive Committee. His five-year term will commence on July 01, 2026, subject to shareholder approval. The company has confirmed that Mr. Mittal is not debarred from holding directorial positions by SEBI or any other regulatory authority.
Leadership Profiles and Experience
Ms. Kiran Mazumdar Shaw brings over four decades of biotechnology experience as the founder of Biocon Group, having led the organization since its inception in 1978. Under her leadership, Biocon has evolved into a global biopharmaceutical enterprise focused on innovation and affordable healthcare. She has received several national and international honors, including the Padma Shri and Padma Bhushan.
Mr. Siddharth Mittal joins from his role as Managing Director and CEO of Biocon Limited, bringing over two decades of experience in strategic finance, mergers and acquisitions, and general management. He initially joined Biocon in May 2013, serving as President & Chief Financial Officer until November 2019.
Strategic Impact and Business Focus
During his tenure at Biocon, Mr. Mittal contributed significantly to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under his leadership, Biocon expanded into complex peptides and GLP-1 therapies, entering strategically significant segments in modern pharmaceuticals.
Visit Our Website : https://leadershipglobalawards.com/
Get Connected Here:
==================
Facebook : https://www.facebook.com/profile.php?...
Twitter : https://twitter.com/Leadership15558
Pinterest : https://in.pinterest.com/leadershipco...
Instagram : https://www.instagram.com/leadershipc...
Comments
Post a Comment